Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
APTX Stock Summary
Top 10 Correlated ETFs
APTX
In the News

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Why Is Aptinyx (APTX) Stock Down 64% Today?
Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary endpoint.

Aptinyx to Present at the SVB Securities Global Biopharma Conference
EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and CMC Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call.

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
EVANSTON, Ill.

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript
Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - President & Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Kathryn King - Senior Vice President, Clinical & CMC Operations Conference Call Participants Ritu Baral - Cowen Evan Hua - BMO Capital Markets Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Second Quarter 2022 Financial Results Conference Call.

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902

Aptinyx to Participate in H.C. Wainwright Global Investment Conference
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022. A webcast recording of the presentat

Aptinyx, Inc. (APTX) CEO Andy Kidd on Q1 2022 Results - Earnings Call Transcript
Aptinyx, Inc. (NASDAQ:APTX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Pat Flavin - IR Andy Kidd - CEO Ashish Khanna - CFO Kathryn King - SVP of Clinical and CMC operations Harald Murck - VP of Medical and Clinical Affairs Conference Call Participants Ritu Baral - Cowen Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Operator Good afternoon, and welcome to the Aptinyx First Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised the call is being recorded at the company's request.
APTX Financial details
APTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.29 | 0.33 | 0.11 | 0.03 | 0.02 | |
Net income per share | -1.91 | -2.64 | -1.71 | -1.02 | 0 | |
Operating cash flow per share | -1.94 | -2.35 | -1.55 | -0.87 | -1.3 | |
Free cash flow per share | -2.04 | -2.37 | -1.55 | -0.87 | -1.3 | |
Cash per share | 5.47 | 7.46 | 2.95 | 2.89 | 2.17 | |
Book value per share | -2.36 | 7.39 | 3.02 | 2.99 | 1.94 | |
Tangible book value per share | -2.36 | 7.39 | 3.02 | 2.99 | 1.94 | |
Share holders equity per share | -2.36 | 7.39 | 3.02 | 2.99 | 1.94 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 339.99M | 334.09M | 114.76M | 169.08M | 130.47M | |
Enterprise value | 247.85M | 183.45M | 15.91M | 28.05M | 24.35M | |
P/E ratio | -10.6 | -6.27 | -2 | -3.38 | 0 | |
Price to sales ratio | 68.52 | 50.82 | 31.28 | 108.11 | 130.47 | |
POCF ratio | -10.39 | -7.04 | -2.2 | -3.99 | -2.06 | |
PFCF ratio | -9.91 | -6.98 | -2.2 | -3.97 | -2.06 | |
P/B Ratio | -8.56 | 2.24 | 1.13 | 1.16 | 1.38 | |
PTB ratio | -8.56 | 2.24 | 1.13 | 1.16 | 1.38 | |
EV to sales | 49.95 | 27.91 | 4.34 | 17.93 | 24.35 | |
Enterprise value over EBITDA | -7.83 | -3.47 | -0.28 | -0.57 | -0.33 | |
EV to operating cash flow | -7.57 | -3.87 | -0.31 | -0.66 | -0.38 | |
EV to free cash flow | -7.22 | -3.83 | -0.31 | -0.66 | -0.38 | |
Earnings yield | -0.09 | -0.16 | -0.5 | -0.3 | 0 | |
Free cash flow yield | -0.1 | -0.14 | -0.45 | -0.25 | -0.49 | |
Debt to equity | -3.45 | 0.04 | 0.05 | 0.03 | 0.21 | |
Debt to assets | 1.41 | 0.04 | 0.05 | 0.03 | 0.18 | |
Net debt to EBITDA | 2.91 | 2.85 | 1.74 | 2.84 | 1.43 | |
Current ratio | 21.74 | 26.04 | 21.47 | 32.64 | 20.18 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 1.02 | 0.89 | 0.91 | 0.85 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.12 | 1.93 | 5.17 | 12.46 | 0 | |
Research and developement to revenue | 6.38 | 7.42 | 12.08 | 20.99 | 55.44 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.01 | 0 | 0.01 | 0 | |
Capex to revenue | -0.32 | -0.06 | -0.01 | -0.14 | 0.12 | |
Capex to depreciation | -3.89 | -0.89 | -0.09 | -0.51 | 0.23 | |
Stock based compensation to revenue | 0.18 | 0.5 | 2.46 | 6.38 | 9.72 | |
Graham number | 10.06 | 20.95 | 10.78 | 8.3 | 0 | |
ROIC | 0.36 | 0.37 | 0.64 | 0.38 | 0 | |
Return on tangible assets | -0.33 | -0.34 | -0.54 | -0.33 | 0 | |
Graham Net | -2.63 | 7.17 | 2.8 | 2.79 | 1.76 | |
Working capital | 90.66M | 147.37M | 100.21M | 145.02M | 109.06M | |
Tangible asset value | -39.72M | 149.31M | 101.31M | 145.91M | 94.76M | |
Net current asset value | -42.01M | 146.95M | 99.94M | 144.91M | 94.57M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 712.5K | 757.5K | 511K | 350.5K | 128.5K | |
Average payables | 1.57M | 1.71M | 1.72M | 1.38M | 915.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 68.92 | 32.09 | 44.17 | 59.98 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 5.3 | 11.37 | 8.26 | 6.09 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.81 | -0.36 | -0.57 | -0.34 | 0 | |
Capex per share | -0.09 | -0.02 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.31 | 0 | -0.29 | -0.26 | 0 | |
Operating cash flow per share | -0.27 | -0.28 | -0.24 | -0.22 | -0.51 | |
Free cash flow per share | -0.27 | -0.28 | -0.24 | -0.22 | -0.51 | |
Cash per share | 1.85 | 1.57 | 1.48 | 1.26 | 0.98 | |
Book value per share | 1.65 | 1.4 | 1.14 | 0.92 | 0.72 | |
Tangible book value per share | 1.65 | 1.4 | 1.14 | 0.92 | 0.72 | |
Share holders equity per share | 1.65 | 1.4 | 1.14 | 0.92 | 0.72 | |
Interest debt per share | 0.21 | 0 | 0.37 | 0.37 | 0.01 | |
Market cap | 158.46M | 180.8M | 153.72M | 37.78M | 24.93M | |
Enterprise value | 47.2M | 74.68M | 77.85M | -22.99M | -41.66M | |
P/E ratio | -1.87 | 0 | -1.94 | -0.53 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -8.51 | -9.49 | -9.65 | -2.56 | -0.72 | |
PFCF ratio | -8.51 | -9.55 | -9.65 | -2.56 | -0.72 | |
P/B Ratio | 1.41 | 1.91 | 1.98 | 0.61 | 0.51 | |
PTB ratio | 1.41 | 1.91 | 1.98 | 0.61 | 0.51 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.23 | -3.9 | -4.03 | 1.36 | 2.86 | |
EV to operating cash flow | -2.54 | -3.92 | -4.89 | 1.56 | 1.21 | |
EV to free cash flow | -2.54 | -3.94 | -4.89 | 1.56 | 1.21 | |
Earnings yield | -0.13 | 0 | -0.13 | -0.47 | 0 | |
Free cash flow yield | -0.12 | -0.1 | -0.1 | -0.39 | -1.39 | |
Debt to equity | 0.18 | 0.21 | 0.38 | 0.49 | 0.56 | |
Debt to assets | 0.16 | 0.18 | 0.27 | 0.33 | 0.36 | |
Net debt to EBITDA | 5.25 | 5.55 | 3.93 | 3.6 | 4.56 | |
Current ratio | 21.07 | 20.18 | 22.49 | 16.22 | 27.45 | |
Interest coverage | 0 | 0 | -40.63 | -22.6 | -17.16 | |
Income quality | 0.88 | 0 | 0.8 | 0.84 | 0.98 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | -0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 3.18 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.42 | 0 | 2.75 | 2.32 | 0 | |
ROIC | 0.18 | 0 | 0.2 | 0.21 | 0 | |
Return on tangible assets | -0.16 | 0 | -0.19 | -0.19 | 0 | |
Graham Net | 1.55 | 1.27 | 1.05 | 0.81 | 0.58 | |
Working capital | 126.12M | 109.06M | 101.79M | 86.46M | 71.26M | |
Tangible asset value | 112.04M | 94.76M | 77.49M | 62.1M | 48.79M | |
Net current asset value | 111.8M | 94.57M | 77.36M | 61.93M | 46.54M | |
Invested capital | 0.13 | 0 | 0.31 | 0.39 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.78M | 1.87M | 1.19M | 1.93M | 1.29M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.19 | 0 | -0.26 | -0.28 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
APTX Frequently Asked Questions
What is Aptinyx Inc. stock symbol ?
Aptinyx Inc. is a US stock , located in Evanston of Il and trading under the symbol APTX
Is Aptinyx Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $1. The lowest prediction is $1 and the highest is $1
What is APTX stock prediction ?
What is Aptinyx Inc. stock quote today ?
Aptinyx Inc. stock price is $0.151 today.
Is Aptinyx Inc. stock public?
Yes, Aptinyx Inc. is a publicly traded company.